Impact of the FDA roadmap and perspectives for regulatory use of new approach methodologies in Japanese pharmaceutical companies

Tetsuro Araki, Hitoshi Naraoka, Yuta Asakawa, Toru Usui, Dai Kakiuchi, Seiichiro Kurashige, Tadahiro Shinozawa, Kimika Nakamura, Takumi Noda, Satomi Nishikawa, Mutsumi Suzuki

Open source

DOI: 10.1016/j.namjnl.2026.100114
Published: 2026
Container: NAM Journal
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.namjnl.2026.100114,
  title = {Impact of the FDA roadmap and perspectives for regulatory use of new approach methodologies in Japanese pharmaceutical companies},
  author = {Tetsuro Araki and Hitoshi Naraoka and Yuta Asakawa and Toru Usui and Dai Kakiuchi and Seiichiro Kurashige and Tadahiro Shinozawa and Kimika Nakamura and Takumi Noda and Satomi Nishikawa and Mutsumi Suzuki},
  year = {2026},
  journal = {NAM Journal},
  doi = {10.1016/j.namjnl.2026.100114},
  url = {https://doi.org/10.1016/j.namjnl.2026.100114}
}

RIS

TY  - JOUR
TI  - Impact of the FDA roadmap and perspectives for regulatory use of new approach methodologies in Japanese pharmaceutical companies
AU  - Tetsuro Araki
AU  - Hitoshi Naraoka
AU  - Yuta Asakawa
AU  - Toru Usui
AU  - Dai Kakiuchi
AU  - Seiichiro Kurashige
AU  - Tadahiro Shinozawa
AU  - Kimika Nakamura
AU  - Takumi Noda
AU  - Satomi Nishikawa
AU  - Mutsumi Suzuki
PY  - 2026
JO  - NAM Journal
DO  - 10.1016/j.namjnl.2026.100114
UR  - https://doi.org/10.1016/j.namjnl.2026.100114
ER  -

APA

Araki, T., Naraoka, H., Asakawa, Y., Usui, T., Kakiuchi, D., Kurashige, S., Shinozawa, T., Nakamura, K., Noda, T., Nishikawa, S., & Suzuki, M. (2026). Impact of the FDA roadmap and perspectives for regulatory use of new approach methodologies in Japanese pharmaceutical companies. NAM Journal. https://doi.org/10.1016/j.namjnl.2026.100114

Source records

crossref · retrieved 2026-09-26T10:13:41.897Z